ceftriaxone/oxacillin — Competitive Intelligence Brief

ceftriaxone/oxacillin (ceftriaxone/oxacillin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic combination. Area: Infectious Disease.

marketed Beta-lactam antibiotic combination Penicillin-binding proteins (PBPs) Infectious Disease Small molecule

Target snapshot

ceftriaxone/oxacillin (ceftriaxone/oxacillin) — UPECLIN HC FM Botucatu Unesp. This combination of two beta-lactam antibiotics inhibits bacterial cell wall synthesis through inhibition of penicillin-binding proteins, providing broad-spectrum coverage against gram-positive and gram-negative bacteria.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ceftriaxone/oxacillin TARGET	ceftriaxone/oxacillin	UPECLIN HC FM Botucatu Unesp	marketed	Beta-lactam antibiotic combination	Penicillin-binding proteins (PBPs)
Pivmecillinam/augmentin	Pivmecillinam/augmentin	Radboud University Medical Center	marketed	Beta-lactam antibiotic combination	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
Prednisolone and amoxicillin/clavulanate	Prednisolone and amoxicillin/clavulanate	University of Chicago	marketed	Corticosteroid + Beta-lactam antibiotic combination	Glucocorticoid receptor (prednisolone); Bacterial peptidoglycan cross-linking (amoxicillin); Beta-lactamase (clavulanate inhibition)
Vonoprazan-Amoxicillin Dual Therapy	Vonoprazan-Amoxicillin Dual Therapy	Nanjing First Hospital, Nanjing Medical University	marketed	Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic combination	H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)
Vonoprazan+amoxicillin 14 days	Vonoprazan+amoxicillin 14 days	Xijing Hospital of Digestive Diseases	marketed	Potassium-competitive acid blocker + beta-lactam antibiotic combination	H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)
Gentamicin + narrow spectrum betalactam	Gentamicin + narrow spectrum betalactam	University Hospital, Akershus	marketed	Aminoglycoside + Beta-lactam antibiotic combination	Bacterial 30S ribosome (gentamicin); Penicillin-binding proteins (beta-lactam)
omeprazole plus amoxicillin	omeprazole plus amoxicillin	National Taiwan University Hospital	marketed	Proton pump inhibitor + beta-lactam antibiotic combination	Proton pump (H+/K+-ATPase) and bacterial cell wall (penicillin-binding proteins)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic combination class)

1. Juan A. Arnaiz · 1 drug in this class
2. National University of Singapore · 1 drug in this class
3. Population Health Research Institute · 1 drug in this class
4. Radboud University Medical Center · 1 drug in this class
5. UPECLIN HC FM Botucatu Unesp · 1 drug in this class